TORONTO--(BUSINESS WIRE)--Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that it has changed its corporate name to Acerus Pharmaceuticals Corporation (“Acerus”, pronounced ay-SAIR-us), effective immediately.
“We are very excited to officially launch our new corporate identity with a name that aligns to our Company’s value proposition,” said Tom Rossi, President and Chief Executive Officer of Acerus. “The name Acerus is derived from the Latin root word acer, and conveys sharp minds and passionate, spirited action as embodied by our current leadership team, employees and partners. Acer is also the genus of trees commonly known as the maple, the official tree and symbol of Canada.”
Trimel shareholders approved the corporate name change at the Company’s Annual General and Special Meeting in June 2015. The Company’s common shares are expected to begin trading under the new ticker symbol TSX:ASP within the next few days, with no impact to current shareholders.
Acerus Pharmaceuticals Corporation, formerly known as Trimel, is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.
Acerus markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO™, a product utilizing an Acerus licensed nasal gel technology, is the first and only testosterone nasal gel approved and launched in the United States for replacement therapy in adult males diagnosed with hypogonadism, and is currently filed for approval in Canada. The commercial rights to NATESTO™ in the United States and Mexico have been licensed by Acerus to an affiliate of Endo International plc. TEFINA™, a ‘use as required’ nasal testosterone gel, is an Acerus drug development candidate aimed at addressing a significant unmet need for women with female orgasmic disorder.
Notice regarding forward-looking statements:
Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 4, 2015 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.